News Breaks |
|
|
| December 10, 2012 |
| 15:28 EDT |  | NSPH | Nanosphere receives FDA clearance for C. difficile test
Nanosphere announced the FDA granted 510(k) clearance permitting marketing of its C.difficile test on the automated sample-to-result Verigene System. The C. difficile test expands Nanosphere's infectious disease test capabilities. C. difficile infection is a cause of diarrhea that can lead to colitis, other serious intestinal conditions and death. In less than two hours, the C. difficile test detects the toxin A and B gene sequences of C. difficile and identifies the PCR ribotype 027 strain which is associated with increased severity of disease and used for infection control. Early and accurate diagnosis of C. difficile infections is critical in both the proper treatment of infected patients and subsequent implementation of isolation and containment procedures to prevent further spread of the infection. |
|
|
News For NSPH From The Last 14 Days Check below for free stories on NSPH the last two weeks. |
|
|
| May 21, 2013 |
| 07:34 EDT |  | NSPH | UBS to host a conference
 Subscribe for More Information |
|
| May 14, 2013 |
| 09:00 EDT |  | NSPH | Nanosphere rises 15.8%
Nanosphere is up 15.8%, or 44c, to $3.23 |
|
| May 13, 2013 |
| 18:56 EDT | | NSPH | On The Fly: After Hours Movers
Subscribe for More Information |
|
| 16:06 EDT | | NSPH | Nanosphere announces agreement with Hitachi High-Technologies
Subscribe for More Information |
|
| May 8, 2013 |
| 08:44 EDT |  | NSPH | Nanosphere backs FY13 revenue guidance of $13M-$15M, consensus $12.97M
Subscribe for More Information |
|
| 08:42 EDT |  | NSPH | Nanosphere sells 1.923M shares of common stock at $2.60
Craig-Hallum is acting as sole book-running manager for the offering. |
|
| 08:42 EDT | | NSPH | Nanosphere reports Q1 EPS (15c), consensus (15c)
Subscribe for More Information |
|
|
|
|
|
